Laurus Labs Ltd

- For FY26, Laurus Labs plans a capex of around INR 1,000 crores, primarily toward CDMO and formulation businesses and fermentation capacity expansion. - Management indicated that debt levels will not significantly increase with this capex; debt may fluctuate around ±10%, roughly INR 250 crores. - They expect to manage capex largely through internal cash flows without major additional borrowing. - No specific plans for equity fundraising were mentioned in the call. - The company aims to maintain a stable balance sheet with net debt/EBITDA ratio improving from 3.1 to 2.3. - Overall, no significant new debt or equity fundraising is projected in the near term.

- FY26 capex is planned around INR1,000 crores. - Major capex focus areas include: - Increasing formulation CMO capacity. - Specific capex for a formulation partner. - Fermentation capacity expansion in Vizag with close to INR250 crores. - Adding production blocks at Vizag for API and CDMO businesses. - No significant increase in debt is expected to support this capex. - No new greenfield facilities are expected to start operations in FY26; expansion is mostly through existing sites. - INR5,000 crores capex announcement includes backward integration and de-risking the supply chain to reduce dependence on China. - Plans for ADC (Antibody-Drug Conjugate) segment include a $15 million investment focusing on conjugation (not mAbs). - Animal Health and Crop Sciences CDMO are commercializing; expect significant revenue jump in FY26 with one more year needed to nurture crop sciences business.

- CDMO segment is expected to grow significantly, driven by ongoing and new projects with big pharma partners, including human health, animal health, and crop sciences divisions. - CDMO revenue contribution increase anticipated to improve overall margins. - ARV revenues expected to remain stable around INR 2,500-2,600 crores in the medium term; no major growth expected there. - Non-ARV formulations sales to rise, especially from approvals in US and Canada and new CMO contracts. - Animal health business to see a significant revenue jump by FY26 post commercial validations. - Crop sciences business is nascent, expected to mature over next year for clearer outlook. - Capex focused on CDMO/CMO expansions, expected to fuel growth in these segments. - Working capital increases due to complex CDMO projects and higher formulation sales expected to normalize. - Overall FY26 outlook anticipates growth in revenues and profitability, with better asset utilization.

- Laurus Labs expects significant growth in revenues and profitability in FY26 compared to FY25, driven notably by the CDMO and formulation segments. - CDMO revenues are projected to grow, with an associated improvement in EBITDA margins as the CDMO share increases. - Overall operating margin is expected to improve due to better asset utilization and enhanced product mix. - Return on capital employed (ROCE) is anticipated to improve from current near-double digit levels but no specific timeline was provided. - Capex of around INR1,000 crore planned for FY26 primarily to expand CDMO/CMO capacities, with minimal increase in debt. - The growth outlook includes strong pipeline projects mostly in late stages (phase 2 and 3), supporting sustained revenue growth. - Management refrains from providing precise numerical financial guidance but is confident on a positive trajectory in earnings and margins over the medium term.

- The active pipeline projects have increased significantly to 110 currently, up from around 60 two to three years ago. - Out of the 110, about 90 projects are in human health and 20 in animal health. - Majority of these projects are in advanced phases, primarily Phase 2 and Phase 3, indicating strong revenue potential. - The number of Requests for Proposal (RFPs) has also seen a significant increase, signaling growing order intake. - CDMO projects are long and complex with longer order-to-delivery timelines, contributing to higher working capital and backlog. - Animal health CDMO is expected to see a significant revenue jump starting FY26 as validations complete and commercial production begins. - Crop sciences CDMO is commercialized recently, with some projects under negotiation and feasibility studies—expected to mature in another year. - Overall, the orderbook indicates robust growth potential especially in the human health and animal health CDMO segments.